Jazz Pharmaceuticals plc — Director's Dealing 2016

Aug 12, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2016-08-12

Reporting Person: Smith Karen L. (Global Head of R&D and CMO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-08-12	Ordinary Shares	P	607.0	$137.0976	Acquired	14181	Direct
2016-08-12	Ordinary Shares	P	1.0	$137.2645	Acquired	14182	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.